logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Michael E Flaugh

This inventor holds 28 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Chemistry. Top assignee: Eli Lilly and Company. Active years: 1978-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael E Flaugh. Retrieved from https://idiyas.com/inventor/michael-e-flaugh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28

% Patents Active = 96.4


Average Co-Inventor Count = 1.6

ph-index = 11

Forward Citations = 330(Granted Patents)


Company Filing History:

goldMedal28 out of 4,514 
 
Eli Lilly and Company
 patents

Years Active: 1978-2007

Loading Chart...
Loading Chart...
Areas of Expertise:
Melatonin Derivatives
Serotonin Agonists
Carboxamides
Tetrahydrobenzindoles
Pharmaceutical Compounds
Ovulation Inhibitors
Desynchronization Disorders
Anti-Androgen Compounds
Hexahydrobenzindoles
Substituted Compounds
28 patents (USPTO):Explore Patents
1. 7230011 - [object Object] (2007-06-12),
2. 6221884 - Carboxamides useful as 5-HT1F agonists (2001-04-24),
3. 6180657 - Melatonin derivatives for use in treating desynchronization disorders (2001-01-30),
4. 6022980 - Preparation of 4-halo and 6-halomelatonins (2000-02-08),
5. 5935992 - Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and (1999-08-10),
6. 5932739 - Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and (1999-08-03),
7. 5846995 - Substituted 1, 2, 3, 4-tetrahydro-2-dibenzofuranamines and (1998-12-08),
8. 5814653 - Pharmaceutical method using 6-substituted-1, 2, 3, (1998-09-29),
9. 5783590 - 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz�CD!indoles (1998-07-21),
10. 5708187 - 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and (1998-01-13),
11. 5654325 - Melatonin derivatives for use in treating sleep disorders (1997-08-05),
12. 5594019 - 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles (1997-01-14),
13. 5470853 - 6-substituted-hexahydrobenz [CD] indoles (1995-11-28),
14. 5462962 - Tetrahydrobenz[c,d]indole serotonin agonists (1995-10-31),
15. 5385928 - Tetrahydrobenz [CD] indazoles, compositions and use (1995-01-31),

Title: Innovations and Contributions of Michael E. Flaugh

Introduction

Michael E. Flaugh is an accomplished inventor based in Indianapolis, IN, who has made significant contributions to the field of pharmaceutical research and development. He is credited with 28 patents, showcasing his innovative spirit and dedication to advancing medical science.

Latest Patents

Among his most recent patents are compounds that serve as antagonists of the 5-HT6 receptor, a critical target in the treatment of various neurological disorders. His work also includes the development of novel 2-amino-1,2,3,4-tetrahydro-9H-carbazole-6-carboxamides and 3-amino-10H-cyclohepta[7,6-b]indole-7-carboxamides, which are classified as carboxamides useful as 5-HT1F agonists. These inventions reflect his commitment to exploring new therapeutic avenues for patients.

Career Highlights

Michael Flaugh is currently affiliated with Eli Lilly and Company, where he continues to innovate and contribute to the development of new drugs. His position within such a reputable institution underlines his expertise and the trust placed in him to drive research efforts forward.

Collaborations

Throughout his career, Flaugh has collaborated with notable colleagues, including Michael J. Martinelli and John M. Schaus. These collaborations have enhanced his work and led to further advancements in their shared field, emphasizing the importance of teamwork in scientific research.

Conclusion

Michael E. Flaugh represents a remarkable example of how ingenuity in the pharmaceutical sector can lead to valuable patents that have the potential to improve healthcare outcomes. His ongoing work at Eli Lilly and Company and his collaborative efforts highlight the importance of innovation in addressing medical challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…